CBD May Improve Neurologic, Cognitive, QOL Outcomes in Sturge-Weber SyndromePosted by On

A small, prospective, open-label trial found evidence of improved quality of life (QOL) and clinical outcomes among patients with treatment-resistant Sturge-Weber syndrome when they were treated with CBD.

Epidiolex (cannabidiol [CBD]) may hold promise for seizure control in treatment-resistant Sturge-Weber syndrome (SWS), according to a new study published in Pediatric Neurology. The prospective, pilot, open-label trial found evidence of improved quality-of-life (QOL) and clinical outcomes, but larger studies are warranted to confirm the drug’s effects in this population.

Seizure management is crucial in SWS, which is characterized by abnormal blood vessels in the brain and skin, and potentially the eyes. Seizure intensity is associated with cognitive outcomes, and seizures increase a patient’s risk of stroke or stroke-like events. CBD is a nonpsychotropic cannabinoid that is FDA approved for medically refractory seizures in Lennox-Gestaut syndrome, Dravet syndrome, and tuberous sclerosis complex.

CBD is also used clinically for patients living with SWS who have treatment-refractory seizures, and a previous study suggests that it may improve cognition, headaches, and other QOL measures in addition to reducing seizures in SWS. The new follow-up trial aimed to determine whether CBD could improve brain function, cognition, psychiatric function, and neurologic function in patients with SWS.

Ten participants were initially included in the study, all of whom had clinically…

Original Author Link click here to read complete story..


Cannabidiolcbdcognitive impairmentDravet syndromeepilepsyLennox-Gestaut syndromepatients with SWSseizuresSturge-Weber syndrome

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.